Although Alzheimer's disease is considered a progressive neurodegenerative process with dementia evolving as the final stage of the disease, neither hippocampal structure assessments nor cerebrospinal fluid (CSF) analyses of amyloid and tau pathology are yet sufficient biomarkers to confirm definitive future development of dementia in patients with MCI. Here, MAPT is linked to dementia.